Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives
Martin Reck, Sanjay Popat, Christian Grohé, J. Corral, Silvia Novello, Maya Gottfried, Wolfgang M. Brueckl, Dejan Radonjic, R. Kaiser, John V. Heymach
Topics & Concepts
MedicineNivolumabPembrolizumabRamucirumabNintedanibAtezolizumabOncologyBevacizumabDocetaxelClinical trialLung cancerInternal medicineImmunotherapyChemotherapyPemetrexedIntensive care medicineCancerLungCisplatinIdiopathic pulmonary fibrosisCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies